Dergoing Transrectal Ultrasound (TRUS) guided prostate biopsy. Abbreviations AS: Active surveillance; EAU: European Association of Urology; HRQOL: Wellness related good quality of life; MRI: Magnetic resonance imaging; PCa: Prostate Cancer; PIL: Patient information leaflet; ProBE: Prostate Biopsy Effects study; Protect: Prostate testing for cancer and Treatment trial, International Regular Randomised Controlled Trial Number 20141297; PSA: ProstateWade et al. BMC Wellness Services Research (2015) 15:Page 9 ofspecific antigen; RCT: Randomised controlled trial; RP: Radical prostatectomy; TRUS-Bx: Transrectal ultrasound guided biopsy. Competing interests The authors declare they have read and understood the BMC Overall health Services Alkaline Phosphatase/ALPL Protein Purity & Documentation analysis policy on declarations of interest and have no interests to declare. Authors’ contributions JW and JLD conceived the study and were mainly responsible for the analysis along with the completed manuscript. JW, JD, KNLA and CES carried out interviews and contributed to evaluation; DJR, JLD, JAL, and FCH devised the ProBE study protocol and arranged integration in to the ongoing Guard study. Defend study funding was obtained by FCH, DEN and JLD. CM supplied statistical experience within ProBE, contributed to data analysis and interpretation and collectively with DJR, JAL and JH contributed to improvement of your revised patient facts. MLG contributed to study design and acted as nurse consultant in ProBE. KNLA and JMB carried out the preliminary qualitative study that highlighted places of concern and contributed towards the ProBE study design. DEN advised on analysis priorities inside ProBE, advised on integration into the ongoing Defend study, and contributed to study design and style. All authors Cutinase Protein Purity & Documentation critically revised the manuscript and revised it for important intellectual content. JW would be the guarantor. All authors study and authorized the final manuscript. Acknowledgements The authors acknowledge the tremendous contributions for the ProBE (Prostate Biopsy Effects) Study Group of Prasad Bollina, Sue Bonnington, Lynn Bradshaw, Debbie Cooper, Liz Down, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pippa Herbert, Peter Holding, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Malcolm Mason, Hilary Moody, James N’Dow, Philip Powell, Alan Paul, Stephen Prescott, Patricia O’Sullivan, Pauline Thompson, and Sarah Tidball; and furthermore for the Guard study group of James Catto, Michael Davis, Andrew Doble. The ProBE study was funded by the UK Prostate Cancer Danger Management Group. The Shield study is funded by the UK National Institute for Overall health Analysis Overall health Technologies Assessment (NIHR HTA) Programme (Projects No. 96/20/ 06, 96/20/99) and can be published in full in Wellness Technologies Assessment. JLD, FCH and DEN are NIHR senior investigators. The Excellent of Life in Protect study was funded by Cancer Research UK. The views and opinions expressed are those of your authors and don’t necessarily reflect those of the HTA programme, NIHR, Cancer Study UK, the NHS or the Division of Health. Author specifics 1 School of Social and Community Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol BS8 2PS, UK. 2Academic Urology Unit, Royal Hallamshire Hospital, University of Sheffield, Sheffield S10 2JF, UK. 3Protect study Urology Investigation, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. 4Oncology Centre, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK. five Nuffield Departme.
